When was MgShell founded?

MgShell was founded in 2019 and raised its 1st funding round 4 years after it was founded.

Where is MgShell located?

MgShell is headquartered in Milano, Italy.

How many employees does MgShell have?

As of Jul 01, 2024, the latest employee count at MgShell is 3.

Is MgShell a funded company?

MgShell is a funded company, having raised a total of $1.83M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 08, 2023.

When was the latest funding round of MgShell?

MgShell's latest funding was a €***** Series A round on Apr 30, 2025, with participation from 5 investors.

Where does MgShell rank among its competitors?

MgShell ranks 6th amongst 32 active competitors, of which 12 are funded. It stands 7th in terms of total funding among its competitors.

Who are the top competitors of MgShell?

MgShell's top competitors include Eyenovia, PolyActiva and iVeena Delivery Systems. Among them, MgShell secured the most recent funding round in April, 2025.

MgShell - 2026 Company Profile, Team, Funding & Competitors

Most viewed in 2019

MgShell is a series A company based in Milano (Italy), founded in 2019 by Marco Ferroni, Francesco De Gaetano, Federica Boschetti and Matteo Giuseppe Cereda. It operates as a Developer of an intraocular device for drug delivery. MgShell has raised $1.83M in funding from investors like Club degli Investitori, Capital Cell and Italian Angels for Biotech. The company has 32 active competitors, including 12 funded and 3 that have exited. Its top competitors include companies like Eyenovia, PolyActiva and iVeena Delivery Systems.

Key Metrics

Founded Year

2019

Location

Milano, Italy

Stage

Series A

Total Funding

$1.83M in 2 rounds

Latest Funding Round

Series A, Apr 30, 2025, €*****

Investors

Club degli Investitori & 7 more

Ranked

6^th among 32 active competitors

Employee Count

3 as on Jul 01, 2024

Similar Companies

Eyenovia & 34 more

View MgShell's full profile

MgShell has raised a total funding of $1.83M over 2 rounds. Its first funding round was on Feb 08, 2023. Its latest funding round was a Series A round on Apr 30, 2025 for €*****. 5 investors participated in its latest round. MgShell has 7 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of MgShell:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 30, 2025	8744397	Series A	2954122	7332664	5233086	7219282
Feb 08, 2023	8236064	Seed	7287471	8790317	Bios Line Holding & 2 more	9773512

Access funding benchmarks and valuations. Sign up today!

View details of MgShell's funding rounds and investors

The founders of MgShell are Marco Ferroni, Francesco De Gaetano, Federica Boschetti and Matteo Giuseppe Cereda. Marco Ferroni is the CEO of MgShell.

Here are the details of MgShell's key team members:

Marco Ferroni: Co-Founder & CEO of MgShell and founder of 1 other company.
Contact Info: 1 email address
Francesco De Gaetano: Co-Founder & CTO of MgShell and founder of 1 other company.
Federica Boschetti: Co-Founder & Scientific Advisor of MgShell.
Matteo Giuseppe Cereda: Co-Founder of MgShell.

View details of MgShell's Founder profiles and Board Members

MgShell's employee count trend

MgShell has 3 employees as of Jul 24. Here is MgShell's employee count trend over the years:

Uncover MgShell's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MgShell include Eyenovia, PolyActiva and iVeena Delivery Systems. Here is the list of Top 10 competitors of MgShell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Eyenovia 2014, New York City (United States), Public	Developer of microdose therapies for treating myopia	$10M	Eshelman Ventures, Wille Finance & 3 others	60/100
2nd	PolyActiva 2010, Melbourne (Australia), Series C	Drug delivery platform	$46.7M	Yuuwa Capital, Brandon Capital & 2 others	49/100
3rd	iVeena Delivery Systems 2012, Salt Lake City (United States), Series B	Develops ocular products for drop-free cataract surgery	$6.43M	HHS, Park City Angels & 2 others	47/100
4th	MediPrint 2001, San Diego (United States), Series A	Developer of technology for ocular drug delivery	$6.97M	-	43/100
5th	Kedalion Thera 2015, Menlo Park (United States), Acquired	Provider of drug delivery system for eye diseases	$5M	Novartis, Lagunita Biosciences	38/100
6th	MgShell 2019, Milano (Italy), Series A	Developer of an intraocular device for drug delivery	$1.83M	PE Industrial, Club degli Investitori & 6 others	40/100
7th	Re-Vana Therapeutics 2015, Belfast (United Kingdom), Series A	Developer of drug delivery platform forophthalmic diseases	$16.7M	Qubis, Clarendon Fund Managers & 11 others	33/100
8th	OcuMedic 2017, Mullica Hill (United States), Unfunded	Developer of drug delivery product for eyes	-	-	27/100
9th	Amorphex 2010, Andover (United States), Seed	Developer of drug delivery device for ophthalmic diseases	$265K	-	27/100
10th	Opharmic 2016, Hong Kong (China), Funding Raised	Developer of non-invasive ocular drug delivery system	-	MedTech Innovator, Pentepebble	27/100